Search clinical trials for: UDCA, Fenofibrate

Total 211 results

Solvay Pharmaceuticals

Completed

A Randomized, Double-Blind Trial Comparing the Efficacy and Safety of Fenofibrate, Metformin, Their Combination and Placebo in Patients With Metabolic Syndrome.

Patients With Metabolic Syndrome

Hungary, Canada, Finland, Italy, Netherlands, Norway, Poland, Romania, Sweden
McGill University Health Centre/Research Institute...

Completed

High-Density Lipoprotein (HDL) Treatment Study

Genetic Diseases, Inborn | Coronary Arteriosclerosis | Hypoalphalipoproteinemias

Canada
The University of Western Australia
National Heart Foundation, Australia

Completed

Pharmacological Regulation of Fat Transport in Metabolic Syndrome

Obesity | Cardiovascular Disease | Hypertriglyceridemia | Lipid Disorders
Pfizer

Completed

Assess HDL-C Increase And Non-HDL Lowering Effect Of Torcetrapib/Atorvastatin Vs. Fenofibrate

Hyperlipidemia

France
Abbott

Completed

A 16 Week Comparative Study of Fenofibrate Versus Ezetimibe as Add-on Therapy to Atorvastatin

Hyperlipidemia
Solvay Pharmaceuticals

Completed

A Controlled-Study of Fenofibrate 145 mg and Ezetimibe 10 mg in Type IIb Dyslipidemic Patients With Features of the Metabolic Syndrome

Hyperlipidemia Combined

Belgium, France, Germany
Solvay Pharmaceuticals

Completed

Fenofibrate in Dyslipidemia and Metformin-Controlled Diabetes

Dyslipidemia/Glucose Metabolism Disorder

Poland, Ukraine, United Kingdom
Solvay Pharmaceuticals

Completed

Acceptability of a Fixed Combination of Fenofibrate and Metformin

Dyslipidemia/Glucose Metabolism Disorder

France
Solvay Pharmaceuticals

Completed

Acceptability Study of a New Fixed Combination of Fenofibrate 80 mg BID and Metformin 1000 mg BID in Type 2 Diabetes and Dyslipidemia

Diabetes Mellitus, Type 2 | Dyslipidemia

France
Solvay Pharmaceuticals

Completed

A Controlled-Study on the Effect of a Combination of Fenofibrate and Metformin on Weight Loss and Weight Loss-Maintenance, in Obese Patients.

Obesity

Finland
Foundation Research, Florida
GlaxoSmithKline; Abbott; Kos Pharmaceuticals

Completed

Study of Niacin and Rosiglitazone in Dysmetabolic Dyslipidemia

Insulin Resistance | Metabolic Syndrome X

United States

Search clinical trials for: UDCA, Fenofibrate

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Cambodia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations